Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility

NCT00630851 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00630851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2002
Completion date
October 31, 2004
Enrollment
249 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease